Go6976 is a novel and potent inhibitor of JAK2 and JAK3 tyrosine kinases both in vitro and in cellular assays

被引：0
|
作者：
Grandage, VL [1 ]
Linch, DC [1 ]
Khwaja, A [1 ]
机构：
[1] UCL Royal Free & UCL Med Sch, Dept Haematol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2005年 / 129卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [31] JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway
    Fang, Juemin
    Chu, Li
    Li, Chunyan
    Chen, Yijing
    Hu, Fei
    Zhang, Xi
    Zhao, Huaxin
    Liu, Zhuqing
    Xu, Qing
    ONCOLOGY REPORTS, 2015, 33 (01) : 494 - 502
  • [32] Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases
    Sahin, Kazim
    Yabas, Mehmet
    Orhan, Cemal
    Tuzcu, Mehmet
    Sahin, Taha K.
    Ozercan, Ibrahim H.
    Qazi, Sanjive
    Uckun, Fatih M.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (04) : 379 - 387
  • [33] Effects of a novel, selective Jak2 inhibitor, AZ60, on STAT5 signaling and cellular growth in Jak2 V617F cell lines
    Gozgit, Joseph M.
    Bebernitz, Geraldine A.
    Patil, Pankaj
    Ye, Minwei
    Wu, Jiaquan
    Ioannidis, Stephanos
    Davies, Audrey
    Wang, Tao
    Huszar, Dennis
    Zinda, Michael
    BLOOD, 2007, 110 (11) : 1039A - 1039A
  • [34] JAK2 TYROSINE KINASE INHIBITOR AG490 SUPPRESSES CELL GROWTH AND INVASION OF GALLBLADDER CANCER CELLS VIA INHIBITION OF JAK2/STAT3 SIGNALING
    Fu, L-X.
    Lian, Q-W.
    Pan, J-D.
    Xu, Z-L.
    Zhou, T-M.
    Ye, B.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2017, 31 (01): : 51 - 58
  • [35] Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor
    Al-Fayoumi, Suliman
    Campbell, Mary S.
    Amberg, Sherri
    Zhou, Huafeng
    Millard, Lindsey
    Dean, James P.
    BLOOD, 2015, 126 (23)
  • [36] Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy
    Bujak, Anna
    Gunerka, Pawel
    Lipner, Joanna
    Mroczkiewicz, Michal
    Stypik, Bartosz
    Turowski, Pawel
    Wieczorek, Maciej
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [37] A novel series of low nM JAK2 selective inhibitors exhibit potent in vitro activities with favorable preclinical properties
    Mak, Chi Ching
    Cao, Jianguo
    Chow, Chun
    Fine, Richard
    Hood, John
    Kang, Xinshan
    Klebansky, Boris
    Lohse, Dan
    McPherson, Andrew
    Noronha, Glenn
    Pathak, Ved P.
    Renick, Joel
    Soll, Richard
    Zeng, Binqi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 785 - 785
  • [38] SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases
    Elliott, Joanne
    Suessmuth, Yvonne
    Scott, Linda M.
    Nahlik, Krystyna
    McMullin, Mary Frances
    Constantinescu, Stefan N.
    Green, Anthony R.
    Johnston, James A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (04): : 576 - 580
  • [39] SOCS3 TYROSINE PHOSPHORYLATION AS A BIG-MARKER FOR THE MYELOPROLIFERATIVE DISORDER-ASSOCIATED MUTANT JAK2 KINASES
    Nahlik, K.
    Elliott, J.
    Suessmuth, Y.
    Scott, L. M.
    McMullin, M. F.
    Constantinescu, S. N.
    Green, A. R.
    Johnston, J. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 358 - 358
  • [40] Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor
    Lou, Yin-jun
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (02) : 212 - 213
12345